Cargando…

A Retrospective Longitudinal Within-Subject Risk Interval Analysis of Immunoglobulin Treatment for Recurrent Acute Exacerbation of Chronic Obstructive Pulmonary Disease

BACKGROUND: Recurrent acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are common, debilitating, costly and often difficult to prevent. METHODS: We reviewed records of patients who had COPD and immunoglobulin (Ig) treatment as adjunctive preventative treatment for AECOPD, and do...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cowan, Juthaporn, Gaudet, Logan, Mulpuru, Sunita, Corrales-Medina, Vicente, Hawken, Steven, Cameron, Chris, Aaron, Shawn D., Cameron, D. William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4641695/ https://www.ncbi.nlm.nih.gov/pubmed/26558756 http://dx.doi.org/10.1371/journal.pone.0142205

Ejemplares similares

Study protocol: a randomized, double-blind, parallel, two-arm, placebo control trial investigating the feasibility and safety of immunoglobulin treatment in COPD patients for prevention of frequent recurrent exacerbations
por: Cowan, Juthaporn, et al.
Publicado: (2018)

A Randomized Double-Blind Placebo-Control Feasibility Trial of Immunoglobulin Treatment for Prevention of Recurrent Acute Exacerbations of COPD
por: Cowan, Juthaporn, et al.
Publicado: (2021)

Complexity in clinical diagnoses of acute exacerbation of chronic obstructive pulmonary disease
por: Pratt, Alexandre J., et al.
Publicado: (2023)

Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations
por: Unninayar, Dana, et al.
Publicado: (2021)

Levels of immunoglobulin isotypes in serum and respiratory samples of patients with chronic obstructive pulmonary disease: protocol for a systematic review and meta-analysis
por: Unninayar, Dana, et al.
Publicado: (2023)

Pulmonary sequelae of SARS-CoV-2 infection and factors associated with persistent abnormal lung function at six months after infection: Prospective cohort study
por: Yazji, Bashour, et al.
Publicado: (2022)

Protocol for updating a systematic review of randomised controlled trials on the prophylactic use of intravenous immunoglobulin for patients undergoing haematopoietic stem cell transplantation
por: Cowan, Juthaporn, et al.
Publicado: (2015)

Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry
por: Abadeh, Armin, et al.
Publicado: (2023)

Cutaquig(®) Is Well Tolerated in Immunodeficient Patients Who Did Not Tolerate Other Subcutaneous Immunoglobulin Products
por: Brownlee, Sydney, et al.
Publicado: (2022)

Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency
por: Dinh, Tri, et al.
Publicado: (2019)

COVID-19 and post-infectious myalgic encephalomyelitis/chronic fatigue syndrome: a narrative review
por: Poenaru, Sonia, et al.
Publicado: (2021)

Clinical outcomes of immunoglobulin use in solid organ transplant recipients: protocol for a systematic review and meta-analysis
por: Cowan, Juthaporn, et al.
Publicado: (2015)

Comparing the Hospital Frailty Risk Score and the Clinical Frailty Scale Among Older Adults With Chronic Obstructive Pulmonary Disease Exacerbation
por: Chin, Melanie, et al.
Publicado: (2023)

Enhancing COVID Rehabilitation with Technology (ECORT): protocol for an open-label, single-site randomized controlled trial evaluating the effectiveness of electronic case management for individuals with persistent COVID-19 symptoms
por: Hatcher, Simon, et al.
Publicado: (2022)

Impact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease
por: Mulpuru, Sunita, et al.
Publicado: (2022)

Antibiotic Retreatment for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
por: Sethi, Sanjay, et al.
Publicado: (2020)

Interval estimation and optimal design for the within-subject coefficient of variation for continuous and binary variables
por: Shoukri, Mohamed M, et al.
Publicado: (2006)

Effect of exacerbations on health status in subjects with chronic obstructive pulmonary disease
por: Nishimura, Koichi, et al.
Publicado: (2009)

Oral antibiotic therapy for the treatment of infective endocarditis: a systematic review
por: Al-Omari, Awad, et al.
Publicado: (2014)

Incidence Rate of Post-Kidney Transplant Infection: A Retrospective Cohort Study Examining Infection Rates at a Large Canadian Multicenter Tertiary-Care Facility
por: Cowan, Juthaporn, et al.
Publicado: (2018)

Case-Ascertainment Models to Identify Adults with Obstructive Sleep Apnea Using Health Administrative Data: Internal and External Validation
por: Kendzerska, Tetyana, et al.
Publicado: (2021)

Virus infection in exacerbations of chronic obstructive pulmonary disease requiring ventilation
por: Cameron, Robert J., et al.
Publicado: (2006)

Hospital Resource Utilization and Patient Outcomes Associated with Respiratory Viral Testing in Hospitalized Patients
por: Mulpuru, Sunita, et al.
Publicado: (2015)

Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study
por: Keith, Paul K., et al.
Publicado: (2022)

2389. Effect of Rezafungin on QT Interval in Healthy Subjects
por: Flanagan, Shawn, et al.
Publicado: (2018)

Changes in Serum Immunoglobulin G Subclasses during the Treatment of Patients with Chronic Obstructive Pulmonary Disease with Infectious Exacerbations
por: Ba Ta, Thang, et al.
Publicado: (2022)

Correction: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real‑world study
por: Keith, Paul K., et al.
Publicado: (2023)

Impact of BMI on exacerbation and medical care expenses in subjects with mild to moderate airflow obstruction
por: Jo, Yong Suk, et al.
Publicado: (2018)

Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease
por: Meng, Weiwei, et al.
Publicado: (2023)

Exercise responses and mental health symptoms in COVID-19 survivors with dyspnoea
por: Milne, Kathryn M., et al.
Publicado: (2023)

Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study
por: Bourque, P. R., et al.
Publicado: (2016)

Cardiorespiratory physiology, exertional symptoms, and psychological burden in post-COVID-19 fatigue
por: Schaeffer, Michele R., et al.
Publicado: (2022)

Establishment of Reference Intervals of Serum Immunoglobulins in Healthy Korean Adults
por: Jang, Jae-Hyuk, et al.
Publicado: (2021)

Acute Exacerbations of Chronic Obstructive Pulmonary Disease
por: Segal, Leopoldo N., et al.
Publicado: (2015)

Frailty is a predictive factor of readmission within 90 days of hospitalization for acute exacerbations of chronic obstructive pulmonary disease: a longitudinal study
por: Bernabeu-Mora, Roberto, et al.
Publicado: (2017)

Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis
por: Díez-Porras, Laura, et al.
Publicado: (2020)

Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias
por: Higo, Hisao, et al.
Publicado: (2022)

Optimal Management of Severe/Refractory Asthma
por: Pakhale, Smita, et al.
Publicado: (2011)

Cellular localization of immunoglobulin within human maglignant melanomata.
por: Lewis, M. G., et al.
Publicado: (1976)

End-of-life care in individuals with respiratory diseases: a population study comparing the dying experience between those with chronic obstructive pulmonary disease and lung cancer
por: Kendzerska, Tetyana, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_02t9f96u0sa9o77hovoajnj3n0